|  |  |
| --- | --- |
|  | |
| Book Name: | [**Medical Science: Trends and Innovations**](https://www.bookpi.org/bookstore/product/medical-science-trends-and-innovations-vol-1/) |
| Manuscript Number: | **Ms\_BPR\_4264** |
| Title of the Manuscript: | **Successful Use of Nivolumab in a Patient with Head and Neck Cancer After Allogeneic Bone Marrow Transplantation** |
| Type of the Article | **Book Chapter** |

|  |  |  |
| --- | --- | --- |
| PART 1: Comments | | |
|  | Reviewer’s comment | Author’s Feedback *(Please correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Please write a few sentences regarding the importance of this manuscript for the scientific community. A minimum of 3-4 sentences may be required for this part.** | **This manuscript highlight the important are in the immunotherapy era, the uses of immune check point inhibitor in transplanted patient, scanty dataespcially on allogenic stem cell transplant in hematological disease** |  |
| **Is the title of the article suitable?**  **(If not please suggest an alternative title)** | **YES** |  |
| Is the abstract of the article comprehensive? Do you suggest the addition (or deletion) of some points in this section? Please write your suggestions here. | **yes** |  |
| **Is the manuscript scientifically, correct? Please write here.** | **yes** |  |
| **Are the references sufficient and recent? If you have suggestions of additional references, please mention them in the review form.**  **-** | **Yes** |  |
| Is the language/English quality of the article suitable for scholarly communications? | Yes |  |
| Optional/General comments | **In the case presentation one point need more clarification, the dose of NIVOLIMAB used not according to the standard doses which 240mg every 2 weeks , why these doses used? (**subsequently, two courses of a chemotherapy regimen comprising nivolumab (140 mg d1) + albumin paclitaxel (200 mg d1, d8) were administered. A CT exam- ination showed stable disease (SD) on March 12, 2019, following which the patient was administered 120 mg of nivolumab once every 2 weeks from March 15 to May 23, 2019.) |  |

|  |  |  |
| --- | --- | --- |
| **PART 2:** | | |
|  | **Reviewer’s comment** | **Author’s comment** *(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)* |
| **Are there ethical issues in this manuscript?** | *(If yes, Kindly please write down the ethical issues here in details)* |  |

|  |  |
| --- | --- |
| **Reviewer Details:** | |
| Name: | **Kakil Rasul** |
| Department, University & Country | **NCCCR, Weil Cornell Medical College, Qatar** |